$2.32T
Total marketcap
$69.65B
Total volume
BTC 56.31%     ETH 10.02%
Dominance
us

Boiron SA BOIRF Stock

$31.50   0.000000%
Add to favorites
Market Cap
$546.91M
LOW - HIGH [24H]
$31.50 - $31.50
VOLUME [24H]
$200.00
P/E Ratio
14.71
Earnings per share
$2.14
ISIN
FR0000061129
Price   Prediction

Boiron SA Price Chart

Sorry, that's all we've gotfor now...

Boiron SA BOIRF Financial and Trading Overview

Boiron SA stock price 31.5 USD
Previous Close 31.5 USD
Open 31.5 USD
Bid 29.3 USD x 10000
Ask 33.1 USD x 10000
Day's Range 31.5 - 31.5 USD
52 Week Range 24 - 32.28 USD
Volume 200 USD
Avg. Volume 8 USD
Market Cap 546.91M USD
Beta (5Y Monthly) 0.217
PE Ratio (TTM) 14.719625
EPS (TTM) 2.14 USD
Forward Dividend & Yield 1.57 (4.97%)
Ex-Dividend Date June 3, 2026
1y Target Est N/A

BOIRF Valuation Measures

Enterprise Value 499.08M USD
Trailing P/E 14.719625
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 1.0914092
Price/Book (mrq) 1.2213833
Enterprise Value/Revenue 0.996
Enterprise Value/EBITDA 7.217

Trading Information

Boiron SA Stock Price History

Beta (5Y Monthly) 0.217
52-Week Change 10.52%
S&P500 52-Week Change 20.36%
52 Week High 32.28 USD
52 Week Low 24 USD
50-Day Moving Average 31.36 USD
200-Day Moving Average 29.73 USD

BOIRF Share Statistics

Avg. Volume (3 month) 8 USD
Avg. Daily Volume (10-Days) 20 USD
Shares Outstanding 17.36M
Float 3.5M
Short Ratio N/A
% Held by Insiders 79.00%
% Held by Institutions 5.37%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 1.35
Trailing Annual Dividend Yield 4.28%
5 Year Average Dividend Yield N/A
Payout Ratio 0.6383
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) December 31, 2025
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 6.51%
Operating Margin (ttm) 11.59%
Gross Margin 72.98%
EBITDA Margin 13.80%

Management Effectiveness

Return on Assets (ttm) 5.46%
Return on Equity (ttm) 8.46%

Income Statement

Revenue (ttm) 501.11M USD
Revenue Per Share (ttm) 28.86 USD
Quarterly Revenue Growth (yoy) -1.40%
Gross Profit (ttm) 365.72M USD
EBITDA 69.15M USD
Net Income Avi to Common (ttm) 32.64M USD
Diluted EPS (ttm) 2.14
Quarterly Earnings Growth (yoy) 165.90%

Balance Sheet

Total Cash (mrq) 79.34M USD
Total Cash Per Share (mrq) 4.57 USD
Total Debt (mrq) 31.48M USD
Total Debt/Equity (mrq) 8.02 USD
Current Ratio (mrq) 2.222
Book Value Per Share (mrq) 25.790428

Cash Flow Statement

Operating Cash Flow (ttm) 53.24M USD
Levered Free Cash Flow (ttm) 53.06M USD

Profile of Boiron SA

Country United States
State N/A
City Messimy
Address 2, avenue de l’Ouest Lyonnais
ZIP 69510
Phone 33 4 78 45 61 00
Website https://www.boiron.fr
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 2364

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sedative PC Granules to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. Further, the company provides Quietude, Rhinallergy, Ribes Nigrum Macerate Glycerin 1 DH Boiron, Sabal serrulata Mother Tincture Boiron, Sevameo, Sinupyl, Sportenine, Stodaline Sugar-Free, Stodal Granules, Stodal Syrup, Storinyl, Sedative PC Sublingual Tablet, Tilia Tomentosa Glycerinated Macerate 1DH Boiron, Varesol, Verrulia, Avenoc Suppository, Calendula Cream, Zelaceo, and Zenalia. It offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is based in Messimy, France.

Q&A For Boiron SA Stock

What is a current BOIRF stock price?

Boiron SA BOIRF stock price today per share is 31.5 USD.

How to purchase Boiron SA stock?

You can buy BOIRF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Boiron SA?

The stock symbol or ticker of Boiron SA is BOIRF.

Which industry does the Boiron SA company belong to?

The Boiron SA industry is Drug Manufacturers - Specialty & Generic.

How many shares does Boiron SA have in circulation?

The max supply of Boiron SA shares is 17.36M.

What is Boiron SA Price to Earnings Ratio (PE Ratio)?

Boiron SA PE Ratio is 14.71962500 now.

What was Boiron SA earnings per share over the trailing 12 months (TTM)?

Boiron SA EPS is 2.14 USD over the trailing 12 months.

Which sector does the Boiron SA company belong to?

The Boiron SA sector is Healthcare.

Select currency